Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...

The stock's fall snapped a three-day winning streak.

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with ...

The startup is developing a kind of macrocyles, which share strengths of both small molecules and biologics, to make oral ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to ...

Underneath we present a selection of stocks filtered out by our screen. Overview: Micron Technology, Inc. is a company that designs, develops, manufactures, and sells memory and storage products ...

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...